1172 consecutive STEMI patients are included. This mainly includes STEMIs due to atherosclerosis, but also other types of STEMI such as MINOCA, SCAD etc.
Please visit the UMCG Research Data Catalogue for more detailed information on our data and samples.
Baseline clinical, laboratory and echocardiographic data is obtained. Follow-up data on clinical events and echocardiographic data is available and is actively being collected. At the time of the STEMI, peripheral blood samples are taken.
Classically, large STEMIs were treated untimely or inadequately resulting in a large infarction size and occurrence of heart failure with reduced ejection fraction (HFrEF). In the current era, with more optimal treatment and secondary prevention, the incidence of HFrEF has decreased, yet the incidence of heart failure with preserved ejection fraction (HFpEF) is rising. CardioLines follows the included patients in their medical status and health records. Through the taken samples at the time of STEMI, we can unravel novel biomarkers and uncover pathophysiology.
Moreover, STEMI patients remain at high risk for subsequent acute coronary syndrome, coronary revascularizations, stroke and death. CardioLines follows all STEMI patients and study the predictors of subsequent ischemic events in the current era of adequate secondary prevention.
University Medical Center Groningen (UMCG)
Department of Cardiology
HPC AB31
9700 RB Groningen
The Netherlands
Visiting address
University Medical Center Groningen (UMCG)
Antonius Deusinglaan 1
9713 AV Groningen
